PT-141 (Bremelanotide) research guide for Berjou. Melanocortin-4 receptor agonist studied for sexual function — covers purity standards, COA testing, and sourcing.
PT-141 (Bremelanotide) in Berjou — Research & Sourcing Guide
For anyone in Berjou looking to source PT-141 (Bremelanotide), the key fact to understand is that this compound is available only through an online research supply market. The upside of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than local retail ever could. Separating genuine research-grade PT-141 (Bremelanotide) from the rest of the market requires three things: an HPLC chromatogram showing ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. What follows is a vendor evaluation and quality guide built specifically around PT-141 (Bremelanotide), covering everything a Berjou researcher needs before placing a first order.
The melanocortin receptor family (MC1R through MC5R) mediates a diverse range of physiological functions, and research peptides like Melanotan-2 and PT-141 (Bremelanotide) act on different receptor subtypes with different research applications. MT-2 has broad melanocortin receptor activity and has been studied for pigmentation (MC1R), appetite suppression (MC4R), and other endpoints. PT-141 is a more specific MC3R/MC4R agonist studied primarily for CNS-mediated effects. For researchers in Berjou designing experiments with PT-141 (Bremelanotide), the specific receptor binding profile determines which outcomes are mechanistically attributable to the compound and which require additional explanation.
Sourcing Research-Grade PT-141 (Bremelanotide)
Quality PT-141 (Bremelanotide) sourcing begins with a useful first test: does this vendor publish batch-specific COAs proactively? Those who make this data freely available are demonstrating research-grade standards. The HPLC purity trace is the most important document in the COA: it should show a clear dominant peak representing PT-141 (Bremelanotide), with negligible secondary peaks representing impurities — purity should be stated as ≥98%. The combination of community consensus and independent COA review is the most effective quality filter — community feedback surfaces systemic problems invisible in one transaction, and vice versa. Bacteriostatic water is the correct reconstitution medium for PT-141 (Bremelanotide) — it contains 0.9% benzyl alcohol that suppresses bacterial proliferation and extends reconstituted shelf life to 4 weeks when kept refrigerated.
Order PT-141 (Bremelanotide) — ships to Berjou
COA-verified · International tracking · Research grade
Safe Research Practices for PT-141 (Bremelanotide)
All use of PT-141 (Bremelanotide) in Berjou or anywhere is research use only — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Reconstitute PT-141 (Bremelanotide) with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Verify the endotoxin level in your PT-141 (Bremelanotide) batch COA before any injectable research application — look for results stated as EU/mg and compare against acceptable research limits for your application. Researchers using PT-141 (Bremelanotide) alongside other research compounds should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What is the regulatory status of PT-141?
PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.
How does PT-141 differ from Melanotan-2?
Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.
What is PT-141?
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.
